BioAge Labs Inc, a biotech targeted on growing therapies for metabolic ailments, filed an SEC submitting to lift as much as $100 million in an preliminary public providing.
The corporate was founded in 2015 and plans to listing on the Nasdaq below the image BIOA. BioAge Labs filed confidentially on Could 31, 2024.
Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing phrases have been disclosed.
The corporate’s lead drug Azelaprag, is an orally accessible small molecule that has been well-tolerated in 265 people throughout eight Part 1 medical trials.
Additionally Learn: Newly Listed Weight problems Participant Fractyl Well being Shares Encouraging Preclinical Information.
In preclinical weight problems fashions, azelaprag demonstrated the flexibility to greater than double the burden loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist whereas restoring wholesome physique composition and enhancing muscle operate.
The corporate plans to evaluate azelaprag’s potential to drive vital enhancements in weight reduction when mixed with a GLP-1R agonist in two Part 2 trials.
The continued STRIDES medical trial will assess azelaprag together with tirzepatide, marketed as Zepbound by Eli Lilly And Co LLY, with topline outcomes anticipated within the third quarter of 2025.
The second Part 2 trial will assess azelaprag together with semaglutide, marketed as Wegovy by Novo Nordisk A/S NVO, with initiation anticipated within the first half of 2025.
BioAge additionally intends to provoke an insulin sensitivity proof-of-concept trial of azelaprag monotherapy within the first half of 2025 to help potential indication enlargement.
The corporate can also be growing orally accessible small-molecule brain-penetrant NLRP3 inhibitors for ailments pushed by neuroinflammation and anticipates submitting an Investigational New Drug utility for an NLRP3 inhibitor within the second half of 2025 and, if cleared, initiating a Part 1 trial within the first half of 2026.
In February, BioAge Labs completed a Sequence D financing spherical of $170 million led by Sofinnova Investments.
Learn Subsequent:
Photograph by Vidmir Rais through Pixabay
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
